Network Insights Methodology Get Access

AstraZeneca

ORG Health Care / Pharmaceuticals Momentum 7.2ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$81B market cap (London-listed), AstraZeneca manufactures oncology, cardiovascular, and respiratory pharmaceuticals. FDA approved baxdrostat in May 2026 as first-in-class aldosterone synthase inhibitor for resistant hypertension, expanding cardiovascular portfolio.

Recent FDA approval of baxdrostat for hypertension treatment; active in oncology and cardiovascular therapeutic areas.
-0.20
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
7.2
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
13
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
FDA European Union PlocamiumAI China Eli Lilly Merck Novartis Europe United Kingdom Supreme Court Pfizer Roche Florida
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-29 2026-05-29 14 0 Degree Mentions
Signal Decomposition
Attention Cascade
0.236
Narrative Drift
0.000
Spectral Shift
4883.359
Sentiment-Momentum Divergence
0.000
Source Concentration
0.518
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
13 Degree Centrality
Ego Network (top connections)
FDA (weight 27.0)European Union (weight 11.0)PlocamiumAI (weight 10.0)China (weight 8.0)Eli Lilly (weight 6.0)Merck (weight 6.0)Novartis (weight 4.0)Europe (weight 3.0) FDAEuropean UnionPlocamiumAIChinaEli LillyMerckNovartisEurope AstraZeneca (degree 13) AstraZeneca
Centrality History
2026-04-29 2026-05-29 14 0 Degree Mentions
EntityWeight StatusFirst Seen
FDA 27 NEW
European Union 11 NEW
PlocamiumAI 10 NEW
China 8 NEW
Eli Lilly 6 NEW
Merck 6 NEW
Novartis 4 NEW
Europe 3 NEW
United Kingdom 3 NEW
Supreme Court 3 NEW
Pfizer 3 NEW
Roche 2 NEW
Florida 2 NEW
Article Coverage (14)
DateLaneTitle
2026-05-26 Healthcare M&A Triple-Negative Breast Cancer Gets First Real Alternative to Chemo as AstraZeneca-Daiichi Drug Wins Approval
2026-05-26 Healthcare M&A Triple-Negative Breast Cancer Gets First Real Alternative to Chemo as AstraZeneca-Daiichi Drug Wins Approval
2026-05-26 Healthcare M&A Triple-Negative Breast Cancer Gets First Real Alternative to Chemo as AstraZeneca-Daiichi Drug Wins Approval
2026-05-26 Healthcare M&A Triple-Negative Breast Cancer Gets First Real Alternative to Chemo as AstraZeneca-Daiichi Drug Wins Approval
2026-05-26 Healthcare M&A Triple-Negative Breast Cancer Gets First Real Alternative to Chemo as AstraZeneca-Daiichi Drug Wins Approval
2026-05-26 Healthcare M&A Triple-Negative Breast Cancer Gets First Real Alternative to Chemo as AstraZeneca-Daiichi Drug Wins Approval
2026-05-12 Healthcare M&A Bristol Myers Races Patent Cliffs With $15.2 Billion Bet on Chinese Drug Portfolio
2026-05-10 Healthcare M&A Daiichi Sankyo Scraps $950 Million ADC Plant as Oncology Buildout Backfires
2026-05-10 Healthcare M&A Windward Bio Raises $165 Million to Challenge Amgen's Asthma Monopoly With Twice-Yearly Shots
2026-05-10 Healthcare M&A Windward Bio Raises $165 Million to Challenge Amgen's Asthma Monopoly With Twice-Yearly Shots
2026-05-10 Healthcare M&A Windward Bio Raises $165 Million to Challenge Amgen's Asthma Monopoly With Twice-Yearly Shots
2026-04-26 Healthcare M&A Kurma Partners Raises 215 Million Euros to Back Biotech Rebels Challenging Pharma Giants
2026-04-26 Healthcare M&A Kurma Partners Raises 215 Million Euros to Back Biotech Rebels Challenging Pharma Giants
2026-04-26 Healthcare M&A Kurma Partners Raises 215 Million Euros to Back Biotech Rebels Challenging Pharma Giants

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-29 ← Intelligence Network